Last updated on September 2017

A randomized,double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib


Other Details:

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Loceted In: Additional Locations, UT USA
  Connect »